drug_type
RELEVANT_DRUG
intervention_type
Biologic - bispecific monoclonal antibody (anti-CLDN18.2 × anti-CD47)
drug_description
Bispecific IgG monoclonal antibody that binds CLDN18.2 on tumor cells and CD47 to localize CD47 blockade to CLDN18.2-positive tumors, enhancing macrophage phagocytosis and antigen presentation.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Bispecific IgG monoclonal antibody that binds CLDN18.2 on tumor cells and CD47 to localize CD47 blockade to CLDN18.2-positive tumors, disrupting the CD47–SIRPα 'don't-eat-me' signal and enhancing macrophage phagocytosis and antigen presentation to drive anti-tumor immunity.
drug_name
Spevatamig (PT886)
nct_id_drug_ref
NCT05482893